- Global Pharma News & Resources

2021 Major Depressive Disorder Pipeline Insight Report: Insights for Approx 50+ Companies and 50+ Pipeline Drugs -

DUBLIN--(BUSINESS WIRE)--The "Major Depressive Disorder - Pipeline Insight, 2021" drug pipelines has been added to's offering.

This "Major Depressive Disorder - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Major Depressive Disorder Emerging Drugs Chapters

This segment of the Major Depressive Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Major Depressive Disorder Emerging Drugs

AXS-05: Axsome Therapeutics

AXS-05 is a novel, oral, investigational drug product under development for the treatment of central nervous system (CNS) disorders. It utilizes Axsome's technology of combining bupropion and dextromethorphan. Dextromethorphan is an NMDA receptor antagonist, sigma-1 receptor agonist, and inhibitor of the serotonin and norepinephrine transporters. Bupropion serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. The U.S. Food and Drug Administration (FDA) has granted Priority Review to Axsome Therapeutics' AXS-05 (dextromethorphan-bupropion).

Cariprazine: Allergan

Cariprazine (VRAYLAR) is an oral, once daily atypical antipsychotic approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder, with a recommended dose range of 3 to 6 mg/day, and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5 to 6 mg/day. The drug is being evaluated in Phase III clinical trials for the treatment of patients with major depressive disorder.

SAGE-217: SAGE therapeutics

SAGE-217 is a novel, highly potent and selective, next-generation, an oral, positive allosteric modulator that has been optimized for selectivity to synaptic and extrasynaptic GABAA receptors. The Binding sites for NASs are distinct from the recognition sites for GABA, benzodiazepines, and barbiturates. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. SAGE-217 is currently being developed for major depressive disorder (MDD) and certain other mood and movement disorders.

Seltorexant: Janssen Research & Development

Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD). The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.

Brexpiprazole: Otsuka Pharmaceutical

Brexpiprazole was discovered by Otsuka and is being co-developed by Otsuka and Lundbeck in Phase III stage of development. The mechanism of action for brexpiprazole in the adjunctive treatment of major depressive disorder or schizophrenia is not fully understood. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity (sub-nanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors.

PRAX 114: Praxis Precision Medicines

PRAX 114 is an orally administered GABAA positive allosteric modulator (PAM) , being developed by Praxis Precision Medicines, for the treatment of epilepsy, depression (depressive disorders in developmental table) and major depressive disorder.

SEP 4199: Sunovion Pharmaceuticals

SEP 4199 is a therapeutic candidate being developed by Sunovion Pharmaceuticals. It is a non-racemic ratio of amisulpride enantiomers. The investigational oral medicine is said to have increased potency for serotonin 5-HT7 receptors relative to dopamine D2 receptors. SEP-4199 was designed to increase levels of serotonin 5-HT7 activity intended to enhance antidepressant efficacy and produce reduced levels of D2 receptor occupancy appropriate for the treatment of bipolar depression.

Major Depressive Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Major Depressive Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Major Depressive Disorder

There are approx. 50+ key companies which are developing the therapies for Major Depressive Disorder. The companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Preregistration include, Axsome Therapeutics.

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Major Depressive Disorder drugs?
  • How many Major Depressive Disorder drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Major Depressive Disorder?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Major Depressive Disorder therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Major Depressive Disorder and their status?
  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • Allergan
  • American BriVision
  • Avanir Pharmaceuticals
  • BioLite, Inc.
  • BlackThorn Therapeutics, Inc.
  • Boehringer Ingelheim
  • Cerecor Inc.
  • Chase Therapeutics Corporation
  • Clexio Biosciences Ltd.
  • e-Therapeutics PLC
  • Fabre-Kramer Pharmaceuticals
  • Gate Neurosciences, Inc
  • GH Research Limited
  • Intra-Cellular Therapies, Inc.
  • Janssen Research & Development, LLC
  • Mapreg
  • MindMed
  • MSI Methylation Sciences
  • Naurex, Inc, an affiliate of Allergan plc
  • Neuralstem
  • Novartis Pharmaceuticals
  • Otsuka Pharmaceutical Co. Ltd.
  • Praxis Precision Medicines
  • Relmada Therapeutics, Inc.
  • SAGE Therapeutics
  • Seelos Therapeutics
  • Sirtsei Pharmaceuticals
  • Small Pharma Ltd
  • Sunovian Pharmaceuticals
  • Sunshine Lake Pharma Co., Ltd.
  • The Emmes Company, LLC
  • VistaGen Therapeutics Inc.
  • Xenon Pharmaceuticals
  • Zhejiang Huahai Pharmaceutical Co., Ltd.

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 10-Jun-2021